Innovation at the Top 10 Global Drug Companies over the last 15 years
Over the last 15 years, according to Forbes, the pharmaceuticals industry has been undergoing somewhat of a drought when it comes to innovation and the creation of groundbreaking new products. However, when looking at the top 10 companies in the world, it is clear to see that some have still been working tirelessly to provide new products over the period. We take a look at the list of leaders
1. Novartis
Novartis is a Swiss-based company that is best
known for its production of Methylphenidate, or Ritalin, the
psychostimulant drug which helps to calm those who suffer from Attention
Deficit Hyperactivity Disorder (ADHD). Over the course of the last 15 years,
the company has released no fewer than 21 products.
These include Glivec, a drug which restricts the
functionality of the receptor tyrosine kinase enzyme in cells
to combat chronic myelogenous leukaemia (CML)
and gastrointestinal stromal tumors among other diseases. Such was
the success of the product that it has now been certified by the FDA to treat
no fewer than 10 cancers.
Novartis hit its highest point in financial terms
during May of last year, when stock prices were at a peak of $61.84, a month in
which the company was given a boost when its Votubia drug was the first to be
approved in Switzerland for the treatment of a benign brain tumour related to
tuberous sclerosis.
2. Merck & Co.
Despite being one of the world's biggest drug
companies, Merck & Co. fell some way behind the leader Novartis in terms of
how many drugs it has released in the last 15 years, clocking up a total of 16.
Perhaps one of its biggest areas of innovation in the
period has been the development and release of Gardasil, which is the world's
only vaccine to protect against Human Papillomavirus (HPV), one of the leading
causes of cervical cancer in young women.
In 1999, the stock of Merck & Co. Soared to an
unprecedented level of $119.186, after it received an investment of $1.8
billion following the joint venture between itself and the merged companies of
Astra, as well as the introduction of the arthritis medication Vioxx.
3. J&J
Johnson & Johnson (J&J) is an American company
which is ranked as the world's most respected by Barron's Magazine. Its
pharmaceuticals division was launched in 2001, and it has since released 15
products into the market.
Its top drugs include such items as Combantrin, a
Pyrantel pamoate product which is used in the treatment of pinworms in people.
One of the peaks over the last ten years for J&J
came when it hit the headlines in June 2001, after a merger was approved with
Alza Corporation, the company which manufactures chemotherapy drug Doxil. At
this time, the stock for J&J would reach an all-time high of $84.71.
4. Pfizer
Pfizer has released a number of high-profile drugs
throughout the last 15 years. However, perhaps its biggest success during this
time has come in the form of Aricept, a drug which is designed to improve the
cognitive functions of people with a mild form of Alzheimer's Disease. It is
the biggest selling product of this type on the market, and one of the 14 that
Pfizer has released over the last 15 years.
The height of the last 15 years for Pfizer came during
June 1999, following a second quarter of that year throughout which the company
reported a high level of revenues, with its products such as Lipitor, Aricept,
and Celebrex selling particularly well.
5. Wyeth
Coming in just below Pfizer is the company which it
bought out in 2009, Wyeth. Before it was made a part of Pfizer, Wyeth
contributed to innovation in the pharmaceutical market with 13 drugs between
1997 and its takeover, including Enbrol, a TNF inhibitor which helps to treat
auto-immune disease by targeting tumour necrosis factors in the brain.
Wyeth was merged in 2009 with Pfizer, which brought to
an end the production of its own drugs.
6. Bristol-Myers Squibb
A relative newcomer when compared to other
companies in the top 10, Bristol-Myers Squibb was formed as recently as 1989
after a merger of its predecessors.
Of its 11 drugs released in the last 15 years, one of
its biggest has been the 2006-approved Atripla, a drug which helped in the
treatment of HIV by becoming one of the first combined daily-dosage drugs.
A peak in its stock prices was seen for Bristol-Myers
Squibb in February of 1999, when it reached the height of $93.16. During this
month, the company and EntreMed Inc. modified their research program into
cancer treatments. It also first saw the operation of a new investment company
it had spent $30 million setting up in Shanghai the month before.
7. Hoffmann-La Roche
Having also released 11 drugs in the period, Swiss
pharma firm Hoffmann-La Roche is another which has had considerable success
with new products since 1997.
It is best known as the maker of the
anti-depressant Valium, but in the last 15 years it has released
such medication as Xenical, an anti-obesity product which is sold
mostly over the counter around the world.
One highlight in terms of stock prices for the Swiss
firm came in December 2004, a year during which Hoffmann-La Roche was granted
FDA approval for the use of its AmpliChip for in vitro diagnostic use as
opposed to simply for research.
8. Lilly
Eli Lilly and Company is an Indiana-based firm,
founded by the chemist of the same name, which sells products in over 125
nations worldwide, and has also released 11 drugs over the past 15 years.
Its innovations include such products as Ciallis, a
PDE5 inhibitor which is used in many countries as a treatment for the common
issue of erectile dysfunction.
Eli Lily's most successful period over the last
15 years came at the very beginning of the period in 1997. In October, the
stock price reached $98.19, just ahead of the company being given approval for
its Evista drug, used in the treatment of Osteoporosis.
9. GlaxoSmithKline
Despite being perhaps the most well known of all
pharma firms worldwide, GlaxoSmithKline has released just 10 drugs in the last
15 years, leaving it a distance behind many others.
The newer products from the company include such drugs
as Coreg, a Carvedilol-based product which is used by doctors to treat
congestive heart failure as a beta-blocker.
In July 2007, the price of shares
in GlaxoSmithKline hit an eight-year high when the company announced
the extension of a buy back scheme for the two years which were to follow.
10. Abbott
The final company to make the top 10 is Abbot
Laboratories, an American firm which has managed to release nine
drug products across the globe throughout the last 15 years.
One of its biggest innovatory products is Humira
(adalimumab), a treatment for rheumatoid arthritis which was the third TNF
inhibitor approved in the US.
Abbot has recently enjoyed a soaring price in its
stocks which saw investors welcoming the best returns in 14 years in early May,
despite the fact that the company had to come to a settlement of $1.5 billion
dollars relating to drug marketing earlier this month.
Fuente: Pharma IQ, a division of IQPC
No comments:
Post a Comment